ACADIA Pharmaceuticals Inc. (ACAD) Expected to Post Quarterly Sales of $56.40 Million
Equities analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to announce sales of $56.40 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for ACADIA Pharmaceuticals’ earnings. The highest sales estimate is $59.90 million and the lowest is $55.00 million. ACADIA Pharmaceuticals posted sales of $35.58 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 58.5%. The company is scheduled to issue its next earnings results on Tuesday, November 6th.
On average, analysts expect that ACADIA Pharmaceuticals will report full-year sales of $220.82 million for the current financial year, with estimates ranging from $217.90 million to $228.70 million. For the next fiscal year, analysts expect that the business will post sales of $308.75 million per share, with estimates ranging from $265.90 million to $383.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.06). The company had revenue of $57.06 million for the quarter, compared to analysts’ expectations of $58.63 million. ACADIA Pharmaceuticals had a negative return on equity of 78.56% and a negative net margin of 135.99%. The business’s revenue for the quarter was up 87.2% on a year-over-year basis. During the same period last year, the company posted ($0.55) EPS.
Large investors have recently added to or reduced their stakes in the business. Creative Planning raised its holdings in shares of ACADIA Pharmaceuticals by 16.6% in the 2nd quarter. Creative Planning now owns 84,607 shares of the biopharmaceutical company’s stock valued at $1,292,000 after acquiring an additional 12,073 shares in the last quarter. UBS Group AG raised its holdings in shares of ACADIA Pharmaceuticals by 103.3% in the 1st quarter. UBS Group AG now owns 439,087 shares of the biopharmaceutical company’s stock valued at $9,866,000 after acquiring an additional 223,065 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $314,000. ING Groep NV purchased a new stake in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at about $6,966,000. Finally, Millennium Management LLC raised its holdings in shares of ACADIA Pharmaceuticals by 662.1% in the 1st quarter. Millennium Management LLC now owns 661,358 shares of the biopharmaceutical company’s stock valued at $14,861,000 after acquiring an additional 574,577 shares in the last quarter. 92.98% of the stock is currently owned by hedge funds and other institutional investors.
ACAD traded up $0.01 during trading on Friday, reaching $14.04. 1,242,400 shares of the company were exchanged, compared to its average volume of 2,759,208. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -5.94 and a beta of 3.64. ACADIA Pharmaceuticals has a 12-month low of $12.77 and a 12-month high of $41.20.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Featured Story: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.